Biodel Inc. (BIOD)
-NasdaqCM 3.28 
0.02(0.61%) May 17, 4:00PM EDT
| Prev Close: | 3.30 |
|---|
| Open: | 3.35 |
|---|
| Bid: | 3.07 x 400 |
|---|
| Ask: | 4.62 x 100 |
|---|
| 1y Target Est: | 5.00 |
|---|
| Beta: | 2.35 |
|---|
| Next Earnings Date: | 9-Aug-13 |
|---|
| Day's Range: | 3.18 - 3.44 |
|---|
| 52wk Range: | 2.13 - 3.82 |
|---|
| Volume: | 277,832 |
|---|
| Avg Vol (3m): | 56,814 |
|---|
| Market Cap: | 46.52M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.59 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BIODEL INC FinancialsEDGAR Online Financials(Fri, May 17)
- BIODEL INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 13)
- Biodel upgraded by Ladenburg ThalmannBriefing.com(Fri, May 10)
- Biodel's CEO Discusses F2Q13 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Biodel Reports Second Quarter Fiscal Year 2013 Financial ResultsGlobeNewswire(Wed, May 8)
- Q2 2013 BIODEL INC Earnings Release - 07:30 am ETCCBN(Wed, May 8)
- BIODEL INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Wed, May 8)
- Biodel to Report Second Quarter Fiscal Year 2013 Financial Results on May 8, 2013GlobeNewswire(Mon, May 6)
- Pivotal Progresses with VascazenZacks(Tue, Apr 16)
- Investor Watch List: Week of April 15 2013at Seeking Alpha(Tue, Apr 16)
- Biodel: Reemerging From Obscurity In 2013at Seeking Alpha(Thu, Apr 11)
- Data on ArQule's ARQ 092Zacks(Wed, Apr 10)
- Pre-Clinical Data on Ariad's IclusigZacks(Tue, Apr 9)
- Strategy is tailored for Biodel resultsoptionMONSTER(Mon, Apr 8)
- ArQule Regains ARQ 092 RightsZacks(Tue, Apr 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | -1.35 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.38 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. The company is involved in developing proprietary formulations of injectable recombinant human in...
View More